107 related articles for article (PubMed ID: 26282944)
1. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.
Breccia M; Efficace F; Sica S; Abruzzese E; Cedrone M; Turri D; Gobbi M; Carella AM; Gozzini A; Usala E; Cavazzini F; Danise P; Tiribelli M; Binotto G; Pregno P; Bocchia M; Gaidano G; Crugnola M; Bonifacio M; Avanzini P; Celesti F; Guella A; Martino B; Annunziata M; Luciano L; Stagno F; Vallisa D; Pungolino E; Iurlo A; Rambaldi A; Nardiello I; Orlandi E; Gambacorti-Passerini C; Alimena G
Leuk Res; 2015 Oct; 39(10):1055-9. PubMed ID: 26282944
[TBL] [Abstract][Full Text] [Related]
2. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
Inokura K; Onishi Y; Shimosegawa K; Okitsu Y; Katsuoka Y; Fujiwara T; Fukuhara N; Ishizawa K; Harigae H
Ann Hematol; 2012 Nov; 91(11):1825-6. PubMed ID: 22543830
[No Abstract] [Full Text] [Related]
3. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
4. Is cure of chronic myeloid leukemia in the third millennium a down to earth target (ed) or a castle in the air?
Raanani P; Granot G; Ben-Bassat I
Cancer Lett; 2014 Sep; 352(1):21-7. PubMed ID: 24486739
[TBL] [Abstract][Full Text] [Related]
5. Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study.
Ishikawa Y; Kiyoi H; Watanabe K; Miyamura K; Nakano Y; Kitamura K; Kohno A; Sugiura I; Yokozawa T; Hanamura A; Yamamoto K; Iida H; Emi N; Suzuki R; Ohnishi K; Naoe T
Cancer Sci; 2010 Oct; 101(10):2186-92. PubMed ID: 20608939
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries.
Geissler J; Sharf G; Bombaci F; Daban M; De Jong J; Gavin T; Pelouchova J; Dziwinski E; Hasford J; Hoffmann VS
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1167-1176. PubMed ID: 28289895
[TBL] [Abstract][Full Text] [Related]
7. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.
Ganesan P; Sagar TG; Dubashi B; Rajendranath R; Kannan K; Cyriac S; Nandennavar M
Am J Hematol; 2011 Jun; 86(6):471-4. PubMed ID: 21538468
[TBL] [Abstract][Full Text] [Related]
8. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
9. Factors Influencing Adherence in Cancer Patients Taking Oral Tyrosine Kinase Inhibitors: A Qualitative Study.
Verbrugghe M; Duprez V; Beeckman D; Grypdonck M; Quaghebeur M; Verschueren C; Verhaeghe S; Van Hecke A
Cancer Nurs; 2016; 39(2):153-62. PubMed ID: 25815430
[TBL] [Abstract][Full Text] [Related]
10. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.
Efficace F; Rosti G; Cottone F; Breccia M; Castagnetti F; Iurlo A; Mandelli F; Baccarani M
Leuk Res; 2014 Mar; 38(3):294-8. PubMed ID: 23906625
[TBL] [Abstract][Full Text] [Related]
11. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
[TBL] [Abstract][Full Text] [Related]
12. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
Gater A; Heron L; Abetz-Webb L; Coombs J; Simmons J; Guilhot F; Rea D
Leuk Res; 2012 Jul; 36(7):817-25. PubMed ID: 22364811
[TBL] [Abstract][Full Text] [Related]
13. Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study.
Leader A; Gafter-Gvili A; Benyamini N; Dreyer J; Calvarysky B; Amitai A; Yarchovsky-Dolberg O; Sharf G; Tousset E; Caspi O; Ellis M; Levi I; Raanani P; De Geest S
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):e351-e362. PubMed ID: 30122203
[TBL] [Abstract][Full Text] [Related]
14. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia.
Breccia M; Alimena G
Cancer Lett; 2014 May; 347(1):22-8. PubMed ID: 24508029
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
17. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
18. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
[TBL] [Abstract][Full Text] [Related]
19. CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase.
Dybko J; Haus O; Jazwiec B; Urbaniak J; Wozniak M; Kaczmar-Dybko A; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
Acta Haematol; 2014; 132(2):166-71. PubMed ID: 24577437
[TBL] [Abstract][Full Text] [Related]
20. Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront.
Breccia M; Molica M; Colafigli G; Zacheo I; Latagliata R; Tafuri A; Alimena G
Leuk Lymphoma; 2015 Jul; 56(7):2206-7. PubMed ID: 25549804
[No Abstract] [Full Text] [Related]
[Next] [New Search]
